Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.


Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
06 2019
Historique:
received: 02 08 2018
accepted: 15 01 2019
pubmed: 2 2 2019
medline: 9 4 2020
entrez: 2 2 2019
Statut: ppublish

Résumé

Although the use of geriatric assessment (GA) in the allogeneic hematopoietic cell transplantation (HCT) setting has been reported, few studies have evaluated the impact of patient-reported function on autologous HCT (autoHCT) outcomes. In this study, GA, including the administration of Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) quality of life tool, was performed in 184 patients age ≥50 years (median age, 61 years; range, 50 to 75 years) before autoHCT. Associations among GA findings, quality of life metrics, and post-transplantation outcomes were evaluated using Cox regression. Indications for autoHCT included multiple myeloma (73%), non-Hodgkin lymphoma (20%), and other disorders (7%). The median progression-free survival (PFS) was 28 months, whereas the median overall survival (OS) was not reached. In unadjusted analysis, both PFS and OS were significantly associated with 5 GA components: limitation in instrumental activities of daily living, patient-reported Karnofsky Performance Status (KPS), and the Physical, Functional, and BMT subscale scores of the FACT-BMT. In multivariate analysis, 3 components-limitation in instrumental activities of daily living, patient-reported KPS, and FACT-BMT Physical subscale-remained predictive of both PFS and OS when adjusted for age, provider-reported KPS, disease status, and HCT comorbidity index. In older adults undergoing autoHCT, limitation in any 1 of 3 patient-reported measures of functional status was independently associated with inferior PFS and OS, even after adjusting for known prognostic factors.

Identifiants

pubmed: 30708189
pii: S1083-8791(19)30086-2
doi: 10.1016/j.bbmt.2019.01.028
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1218-1224

Informations de copyright

Copyright © 2019 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Auteurs

Mariam T Nawas (MT)

Memorial Sloan Kettering Cancer Center, New York, New York.

Charalambos Andreadis (C)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Thomas G Martin (TG)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Jeffrey L Wolf (JL)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Weiyun Z Ai (WZ)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Lawrence D Kaplan (LD)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Gabriel N Mannis (GN)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Aaron C Logan (AC)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Lloyd E Damon (LE)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Chiung-Yu Huang (CY)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Rebecca L Olin (RL)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. Electronic address: rebecca.olin@ucsf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH